Visionflex Group Limited · ASX:VFX
Visionflex — Investor Presentation (November 2024)
27 slides from Visionflex's investor presentation, Nov 13, 2024
Slide 1: Investor Presentation Capital Raise
ASX:VFX Investor Presentation Capital Raise NOVEMBER 2024 This announcement was approved for release by the Board of Directors. INVESTOR PRESENTATION / NOVEMBER 2024 / 1
Slide 2: The Visionflex mission
The Visionflex mission Empowering health practitioners globally with cutting edge technologies to elevate patient outcomes. PROPRIETARY PROPRIETARY HARDWARE SOFTWARE CL E A R P A T HWA Y T O P ROF I T A B I L I T Y THIRD PARTY HARDWARE Visionflex proprietary hardware and software connect a range of
Slide 3: Executive Summary
Executive Summary Need for Flagship customer sales In-demand Accelerating growth A clear pathway to Virtual Care & momentum product suite in ARR profitability • Progressive rise in chronic • WA PHA1 (Aged Care): • Early entry benefit across • $1.5m in ARR (30 Sept 2024)3 • FY24 Revenue of $7.0m5 up
Slide 4: Structural Problems Driving a Shift to Virtual Care
Structural Problems Driving a Shift to Virtual Care THE PROBLEM THE SOLUTION Globally, healthcare is experiencing: Adoption of virtual care enables health care providers to deliver: CONSTRAINED CAPACITIES SURGE IN EXPENDITURE MORE CONSULTATIONS INCREASED EFFICIENCY Healthcare globally experiencing E
Slide 5: Hardware
Hardware Visionflex hardware enables health practitioners to virtually conduct medical examinations with confidence and serves as a foundational step for establishing long term software subscriptions. PERIPHERALS + SOFTWARE DEVICE + PERIPHERALS + SOFTWARE MEDICAL CART + PERIPHERALS + SOFTWARE Mobile
Slide 6: Proprietary Software (Virtual Care Platform)
Proprietary Software (Virtual Care Platform) A virtual healthcare platform allowing practitioners to virtually examine, diagnose, monitor, and treat patients. Perform collaborative, clinical, evidence-based consultations between clinicians A user-friendly video conferencing platform that delivers he
Slide 7: Visionflex Revenue Model
Visionflex Revenue Model Offering Core HARDWARE SOFTWARE Key Product / Services Revenue RECURRING REVENUE Streams UPFRONT / ONE-OFF $5k – $30k per unit depending on solution ~$5k per annum for annual software license margin 60-65% GP margin 90-95% GP margin GP Revenue Repeat Each new software licens
Slide 8: Customers and Market Positioning Progress
Customers and Market Positioning Progress INVESTOR PRESENTATION / NOVEMBER 2024 / 88
Slide 9: Strong momentum in key industry verticals
Strong momentum in key industry verticals PRIMARY HEALTH NETWORKS AGED CARE RESOURCE SECTOR LOCAL HEALTH DISTRICTS INDIGENOUS HEALTH & OTHER HEALTH BODIES INTERNATIONAL INVESTOR PRESENTATION / NOVEMBER 2024 / 9
Slide 10: Recent client wins in key industry verticals
Recent client wins in key industry verticals Flagship customers highlighting ‘land and expand’ opportunity. CLIENT CONTRACT VALUE IMPACT OPPORTUNITY • 180 licences (sites) • $2.3m of upfront • Flagship contract highlight's ability to win large • Given referenceabilty with flagship WA PHN, ability to
Slide 11: Opportunities to expand in key industry verticals
Opportunities to expand in key industry verticals INDIGENOUS HEALTH AGED/HOME CARE RESOURCE SECTOR CORRECTIONAL FACILITIES • NACCHO is the national peak body • Residential Aged Care: There are 886 • Global operations in remote and • There are 116 custodial correctional representing 145 Aboriginal He
Slide 12: International expansion – a near growth driver
International expansion – a near growth driver AGENCY 2 PARTNERSHIPS Visionflex products have UK & Europe generated over $1m in revenue in the past from Americas, Europe and Asia. $0.3m of sales to customers in 6 AGENCY 1 overseas countries in FY24. PARTNERSHIPS AGENCY 3 PARTNERSHIPS Americas Untapp
Slide 13: FY24 Financial Overview
FY24 Financial Overview INVESTOR PRESENTATION / NOVEMBER 2024 / 1 13 3
Slide 14: FY24 Financial Dashboard
FY24 Financial Dashboard $6.95m $6.95m Subscription $0.3m Australia $0.3m Hardware Overseas Other Revenue Revenue (By Type) $2.6m $6.0m (By Region) $2.6m $6.6m $0.1m $0.3m $2.3m $2.3m $0.2m $0.7m FY23 FY24 FY23 FY24 $1.3m FY23 FY24 ($0.7m) ARR Underlying Growth EBITDA $0.3m ($3.2m) FY23 FY24 INVESTO
Slide 15: Profit & Loss
Profit & Loss Strong Visionflex revenue growth while tightly managing the cost base to drive near-term profitability 1• Subscription recurring revenue of Note: Presented below is the Visionflex division P&L (including corporate costs), which provides a better representation of the underlying $0.7m,
Slide 16: Balance Sheet
Balance Sheet Improved balance sheet provides operating flexibility to pursue growth opportunities; proforma net assets (post raise) of ~$(1.0m) •1 $1.2m cash at bank with further $1.0m received post capital raise (net of debt repayments and Offer costs). 1 •2 Income tax refund (R&D tax 2 receivable
Slide 17: Outlook
Outlook INVESTOR PRESENTATION / NOVEMBER 2024 / 1 17 7
Slide 18: Summary – Next chapter in Visionflex Journey
Summary – Next chapter in Visionflex Journey 1 Clear strategic plan to deliver profitable growth: 2 Transitioning to recurring revenue via SaaS: • On track to be EBITDA positive in FY25, after investment in key growth • Transition to SaaS pricing delivering growth in annual recurring revenue (ARR).
Slide 19: Capital Raising
Capital Raising INVESTOR PRESENTATION / NOVEMBER 2024 / 1 19 9
Slide 20: Capital Raise – Key Details
Capital Raise – Key Details • Placement to raise $1.75m, via the issue of approximately 437.5 million fully paid ordinary under the Company’s existing Placement capacity per Offer Type ASX Listing Rules 7.1 (collectively, the ‘Offer’) All shares under the Offer will be issued at a fixed price of $0.
Slide 21: Capital Raise – Indicative Timetable
Capital Raise – Indicative Timetable1,2 KEY EVENT DATE Trading Halt commences Monday 11 November 2024 Announcement of Placement and Trading Halt ceases Wednesday 13 November 2024 Settlement of New Shares issued under the Placement Wednesday 20 November 2024 Allotment of New Shares issued under the P
Slide 22: Appendix
Appendix INVESTOR PRESENTATION / NOVEMBER 2024 / 222 2
Slide 23: Board and Executive Management Team
Board and Executive Management Team EXECUTIVE LEADERSHIP TEAM Joshua Mundey Michael Kafrouni James Aulsebrook CH I E F E X E CU T I V E OF F I CE R CH I E F OP E R A T I NG OF F I CE R CH I E F F I NA NCI A L OF F I CE R • Former Co-Founder & Chief Growth Officer at • 15+ years’ experience as a seni
Slide 24: Corporate history
Corporate history • Incorporation of Visionflex Pty Ltd (2014) • Reinstatement to ASX and company • R&D and patents related to ISO 14971 Medical Device Risk Management (2015-2016) renamed to Visionflex Group Limited • GEIS® camera launch (2016) • Accelerated growth of Visionflex • MyHealth1st (MH1)
Slide 25: Capital structure
Capital structure COMPANY PROFILE AS AT 8 NOVEMBER 2024* VISIONFLEX GROUP (VFX) STOCK CHART Shares on Issue 2,917,824,527 (November 2023 to November 2024) Share Price $0.005 $0.014 8.0m Volume (RHS) Share Price (LHS) Share Price ($) Volume Market capitalisation $14.6m $0.012 7.0m Options on Issue (u
Slide 26: Important notices
Important notices This Investor Presentation (Presentation) has been prepared by Visionflex Group Limited ACN 138 897 533 (ASX:VFX) (Company) and is dated 8 rounding. Accordingly, the actual calculations of these figures may differ from the figures set out in this Presentation. November 2024. Accept
Slide 27: Visionflex Group Limited
Visionflex Group Limited Unit 1, 8 Prosperity Parade, Warriewood NSW 2102 VFX-GROUP.COM Joshua Mundey CHIEF EXECUTIVE OFFICER E: jmundey@visionflex.com INVESTOR PRESENTATION / NOVEMBER 2024 / 227 7
Visionflex Group — Investor Presentation (November 2024) on 6ix